



## THE RISK OF ALLOGRAFT IMMUNOLOGIC REJECTION AFTER ULTRATHIN DSAEK

Massimo Busin, MD, Silvana Madi, MD, Paolo Santorum, MD, Cataldo Russo, MD.



Abstract PO074


## **Financial Disclosure Massimo Busin Has Received Travel Expenses and Royalties From Moria Antony, France** (L,P)Silvana Madi, Paolo Santorum and Cataldo Russo Have No **Financial Interest to Disclose.**



#### **SUBJECTS AND METHODS** ✓ UT-DSAEK since 2009 ✓ F/u ≥ 1 Year (Mean=15.7 Mos) = 162 Eyes ✓ Low-Risk Eyes n = 141 ✓ High-Risk Eyes n = 21 **Previous Graft** n = 15 Corneal Vascularization n = 6All Procedures Performed by the Same Surgeon (M.B) ✓ Outcomes Measures: Rejection Rate Rejection Probability

## SURGICAL TECHNIQUE

**UT-DSAEK** as per **Standard DSAEK Except for:** ✓ Donor Tissue **Preparation** ✓ Graft Delivery with Modified **Busin Glide** 



#### **DONOR TISSUE PREPARATION**

- ✓ Bottle at 120 cm (Pressure ±80-90 mm Hg)
   ✓ Clamp at 50 cm to Close System
- 3-Piece Artificial Anterior Chamber
  - Intraoperative Pachymetry
- First Cut with 300 μm
  Microkeratome Head
- Move Dove Tail 180°, Repeat Pachymetry and 2<sup>nd</sup> Cut from Opposite Direction










## **POSTOPERATIVE TREATMENT Topical Dexamethasone 0.1%** Tapered off over a 5-month Period (from 2-Hourly to qd) • qd Lifelong (unless Contraindicated)

For Eyes at High Risk 1.0-1.5 mg/Kg Prednisone p.o. Tapered off over a 2-month Period

# RESULTS

 ✓ Endothelial Rejection in 4/162 Eyes (2.47%)
 Low Risk n=3/142(2.1%)
 High Risk n=1/21 (4.8%)

 All Cases Resolved with Steroidal Treatment !!!



## RESULTS

Kaplan-Meier Probability of Rejection Episode 1 year = 2.5% 2 years = 2.5%



#### **DSAEK/UT-DSAEK/DMEK Cumulative Probability (K-M) DSAEK\*** UT DMEK 1% 6% **1 Year** 2.5% 1% **2 Years 10%** 2.5%

**\*Fuchs Indications Only** 

# CONCLUSION

**Immunologic Rejection After UT-DSAEK Is Very Rare Even In Eyes At High Risk Because of Previous Keratoplasty and/or Corneal Neovascularization**